The study did not meet the primary end point. After a period of one year, in the intention to treat (ITT) population, 97.5% of patients who received triptorelin achieved castrate levels of testosterone by day 29 and 93% of patients maintained that for 12 months.r
Serum testosterone and PSA level in the ITT population:r
© Clin Drug Investig 2009
The two trials triptorelin emboate vs leuprorelin were compared after a period of one year.r
Comparison of results leuprolide acetate with triptorelin pamoate:r
|Castration efficacy <50ng/dL
Patients receiving the 6 month formulations also reported better quality of life (QOL). The main advantages documented were reduced anxiety, decreased emotional burden, improved flexibility with scheduling, less frequent injections, improved comfort, fewer doctor visits, decreased site reactions, decreased cost and less missed visits.